Dr. Treon on Breakthroughs in Waldenström's Macroglobulinemia

Steven Treon, MD, PhD
Published: Friday, Feb 20, 2015



Steven Treon, MD, PhD, Director, Bing Center for Waldenström's Macroglobulinemia and physician at Dana-Farber Cancer Institute, discusses the game changing discoveries in Waldenström’s Macroglobulinemia (WM) that led to the approval of ibrutinib for treatment of the disease.

Until recently, researchers did not understand the genetic basis of WM and had to rely on therapies designed to treat lymphoma and myeloma.

Three years ago, researched discovered that a mutation in the MYD88 gene was present in over 90% of the patients with WM. Researchers were then able to identify the important signaling pathways that are triggered by this mutation.

The discovery of the CR4 mutation, which is present in about one-third of patients with WM, provided further understanding the disease. These two breakthroughs paved the way for the approval of ibrutinib, which Treon says is a ‘game changer’ for the disease.

<<< View more from the 2015 Congress on Hematologic Malignancies



Steven Treon, MD, PhD, Director, Bing Center for Waldenström's Macroglobulinemia and physician at Dana-Farber Cancer Institute, discusses the game changing discoveries in Waldenström’s Macroglobulinemia (WM) that led to the approval of ibrutinib for treatment of the disease.

Until recently, researchers did not understand the genetic basis of WM and had to rely on therapies designed to treat lymphoma and myeloma.

Three years ago, researched discovered that a mutation in the MYD88 gene was present in over 90% of the patients with WM. Researchers were then able to identify the important signaling pathways that are triggered by this mutation.

The discovery of the CR4 mutation, which is present in about one-third of patients with WM, provided further understanding the disease. These two breakthroughs paved the way for the approval of ibrutinib, which Treon says is a ‘game changer’ for the disease.

<<< View more from the 2015 Congress on Hematologic Malignancies




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x